Acromegaly - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 84 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acromegaly - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acromegaly - Pipeline Review, H2 2014', provides an overview of the Acromegaly's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acromegaly
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acromegaly and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acromegaly products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acromegaly pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acromegaly
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acromegaly Overview 8
Therapeutics Development 9
Pipeline Products for Acromegaly - Overview 9
Pipeline Products for Acromegaly - Comparative Analysis 10
Acromegaly - Therapeutics under Development by Companies 11
Acromegaly - Therapeutics under Investigation by Universities/Institutes 13
Acromegaly - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acromegaly - Products under Development by Companies 17
Acromegaly - Products under Investigation by Universities/Institutes 18
Acromegaly - Companies Involved in Therapeutics Development 19
Ipsen S.A. 19
Novartis AG 20
Antisense Therapeutics Limited 21
Paladin Labs Inc. 22
Italfarmaco S.p.A. 23
GP Pharm, S.A. 24
Aegis Therapeutics, LLC 25
Peptron, Inc. 26
Q Chip Ltd. 27
Crinetics Pharmaceuticals, Inc. 28
Chiasma, Inc. 29
Foresee Pharmaceuticals, LLC 30
DexTech Medical AB 31
Acromegaly - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
pasireotide LAR - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
octreotide acetate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ATL-1103 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DG-3173 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
octreotide acetate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CAM-2029 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
octreotide acetate LAR - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Somadex - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ITF-2984 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
octreotide acetate SR - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
SXN-101959 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Proteins to Antagonize Growth Hormone Receptor for Acromegaly - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
FP-002 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
octreotide SR - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
octreotide - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
G-02113 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SXN-101742 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
L-779976 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Acromegaly - Recent Pipeline Updates 63
Acromegaly - Dormant Projects 71
Acromegaly - Discontinued Products 72
Acromegaly - Product Development Milestones 73
Featured News & Press Releases 73
Jul 29, 2014: ATL1103 Acromegaly Phase II Trial Dosing Completed 73
Jul 22, 2014: Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 73
Jul 07, 2014: Allowance of Canadian Patent on ATL1103 & Development Update 74
May 05, 2014: Novartis drug Signifor LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues 74
Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study 76
Mar 21, 2014: ATL1103 Acromegaly Phase II Trial Recruitment Completed 76
Jan 07, 2014: Antisense Therapeutics Selected to Present at Biotech Showcase 2014 77
Dec 23, 2013: Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial 78
Nov 26, 2013: ATL1103 Phase II Trial Update 80
Oct 17, 2013: ATL1103 Phase II Trial Update - Interim Analysis 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables
Number of Products under Development for Acromegaly, H2 2014 9
Number of Products under Development for Acromegaly - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Acromegaly - Pipeline by Ipsen S.A., H2 2014 19
Acromegaly - Pipeline by Novartis AG, H2 2014 20
Acromegaly - Pipeline by Antisense Therapeutics Limited, H2 2014 21
Acromegaly - Pipeline by Paladin Labs Inc., H2 2014 22
Acromegaly - Pipeline by Italfarmaco S.p.A., H2 2014 23
Acromegaly - Pipeline by GP Pharm, S.A., H2 2014 24
Acromegaly - Pipeline by Aegis Therapeutics, LLC, H2 2014 25
Acromegaly - Pipeline by Peptron, Inc., H2 2014 26
Acromegaly - Pipeline by Q Chip Ltd., H2 2014 27
Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2014 28
Acromegaly - Pipeline by Chiasma, Inc., H2 2014 29
Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H2 2014 30
Acromegaly - Pipeline by DexTech Medical AB, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Acromegaly Therapeutics - Recent Pipeline Updates, H2 2014 63
Acromegaly - Dormant Projects, H2 2014 71
Acromegaly - Discontinued Products, H2 2014 72